Prothrombin complex concentrates.

J A Penner

Home/Archive/PubMed

PubMed · 617787

Prothrombin complex concentrates.

J A Penner

View original source ↗Export metadata ↓

Abstract

The use of the prothrombin complex products for the treatment of inhibitor patients is discussed in relation to our difficulty in identifying the effective therapeutic principle, as well as the factors responsible for thrombogenicity. It would appear that combination of factors is responsible for either or both therapeutic and thrombogenic phenomena. Possible intermediate or aggregate forms of the procoagulants are present in the products, protected from the neutralizing effects of antithrombin III.

Explore related subjects

Antithrombin III Blood Coagulation Factor IX Factor V Factor VII Factor XI Factor XII Hemophilia B Humans Prothrombin Prothrombin Time Thrombin Thromboplastin Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J A Penner. 1977. Prothrombin complex concentrates.. https://pubmed.ncbi.nlm.nih.gov/617787/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Prolonged coagulation instability is associated with a higher-dose regimen of tissue-type plasminogen activator in patients with acute myocardial infarction.

Explore the source record for details and available documents.

Antithrombin III↗

PubMed1992

[Antithrombin III. Structure, pathophysiology, determination and therapeutic importance].

The article is devoted to the coagulation proteinases inhibitor antithrombin III which plays an important role in the processes of blood coagulation. The molecular and gene structure, physiology and pathophysiology, assays and therapeutical meanings are dealt with.

Antithrombin III↗

PubMed1992

Two new nonsense mutations in type Ia antithrombin III deficiency at Leu 140 and Arg 197.

Using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and DNA sequencing, the molecular basis of hereditary type Ia antithrombin III (AT III) deficiency was disclosed in two families. One mutation was a change from T to A in the codon of TTA for Leu 140 forming a stop codon of TAA, which was confirmed by mutated primer-mediated PCR-HindIII digestion. The application of this method demonstrated that all four affected members had the mutant allele in a heterozygous state and that none of unaffected subjects had this mutation. Another mutation in the second family was a change from C to T in the codon of CGA for Arg 197 also forming a stop codon of TGA, which was confirmed by PCR-HaeIII digestion. Based on these, it was concluded that the two new nonsense mutations in the AT III gene in a heterozygous state are the molecular basis of hereditary type Ia AT III deficiency.

Antithrombin III↗